KyungDong Pharm home
Prescription Medicines

Stamezin Tab. 50/850mg

Product Category
diabetes medication
Active Ingredients
Sitagliptin phosphate, metformin hydrochloride
Appearance
Pink oval film-coated tablets
Reimbursement Code
648103640
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredients: Sitagliptin phosphate (in-house specification) · · · · · · · 62.04mg (50mg as sitagliptin), metformin hydrochloride (USP) · · · · · · · 850mg
- Additives: Sodium lauryl sulfate, microcrystalline cellulose, Opadry II pink (85F640031) or Tabshield pink (21P677), povidone, sodium stearyl fumarate

2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve glycemic control in patients with type 2 diabetes for whom concurrent administration of sitagliptin and metformin is appropriate.

3. Dosage and dosage
In anti-diabetic therapy, the dosage of this drug is determined considering each patient's current treatment regimen, effectiveness, and tolerability within a range that does not exceed the maximum recommended daily dose of each ingredient, 100 mg of sitagliptin and 2,000 mg of metformin.
This drug is generally taken twice a day with food, and the dosage is gradually increased to reduce gastrointestinal side effects caused by metformin.
The initial dose of this drug is determined according to the patient's current treatment regimen.
1. Patients not currently being treated with metformin:
If you have never received diabetes medication before and have difficulty controlling blood sugar levels with monotherapy, or if you cannot control blood sugar levels sufficiently with sitagliptin alone, take the initial dose of this drug at 50/500 mg twice a day, one tablet at a time. The dose can be increased to 50/1000 mg twice a day, one tablet at a time.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not switch to this drug (see Precautions for Use 2. Do not administer to the following patients).
2. Patients being treated with metformin:
- The recommended initial dose of this drug for patients who cannot adequately control blood sugar levels with metformin monotherapy is sitagliptin 50 mg twice daily (total dose 100 mg per day) and the existing dose of metformin.
- Patients switching from the combination therapy of sitagliptin and metformin to this drug can start with the existing dose of sitagliptin and metformin.
3. When sufficient blood sugar control cannot be achieved with combination therapy of metformin and sulfonylurea, combination therapy of metformin and insulin, or combination therapy of metformin and thiazolidinedione:
The initial dose of this drug is sitagliptin 50 mg twice a day (total dose of 100 mg per day), and the initial dose of metformin should take into account the patient's blood sugar level and existing dosage. To reduce gastrointestinal side effects caused by metformin, gradually increase the dose. When co-administered with sulfonylurea or insulin, a reduction in the dose of sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea or insulin-induced hypoglycemia (see Precautions for Use 5. General Precautions).
No studies have been conducted to examine the safety and effectiveness of switching to this drug in patients previously treated with other oral hypoglycemic agents. Any change in type 2 diabetes treatment regimen may cause changes in glycemic control, so caution should be exercised and appropriate monitoring should be performed.
patients with renal impairment
This drug can be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) without other symptoms that may increase the risk of lactic acidosis by adjusting the dose as follows.
The starting dose of metformin is 500 mg or 850 mg once daily, so treatment with this drug should not be started. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months.
If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.
Hepatic impairment patients
This drug should not be administered to patients with liver dysfunction due to the metformin component (see Precautions for Use 2. Do not administer to the following patients).

4. Precautions for use
1. Warning
Sitagliptin
1) Hypersensitivity reactions: Severe hypersensitivity reactions have been reported in patients who administered this drug after marketing, and these reactions include anaphylaxis, angioedema, and exfoliative skin disease, including Stevens-Johnson syndrome. Because they are voluntarily reported from an unspecified population, it is generally not possible to reliably predict their frequency or establish a causal relationship with drug exposure. The onset of this reaction occurred within the first 3 months of drug treatment and has also been reported after the first dose. If a hypersensitivity reaction is suspected, discontinue this drug, evaluate other potential reasons for the occurrence, and implement another diabetes treatment regimen [4. Adverse reactions, see section 2) Post-marketing adverse reactions].
2) Pancreatitis: Acute pancreatitis, including fatal/non-fatal hemorrhagic or necrotizing pancreatitis, has been reported in patients receiving sitagliptin [4. See Adverse Reactions]. After starting treatment with this drug, carefully observe whether symptoms of pancreatitis appear. If pancreatitis is suspected, administration of this drug and other suspected drugs should be discontinued.
metformin hydrochloride
It may cause severe lactic acidosis or hypoglycemia. Cases of death due to lactic acidosis have been reported.

2. Do not administer to the following patients
1) Patients with moderate (stage3b) and severe renal impairment (creatinine clearance <45 mL/min or glomerular filtration rate <45 mL/min/1.73 m2), acute conditions that may affect renal function such as dehydration, serious infection, cardiovascular collapse (shock), acute myocardial infarction, and sepsis.
2) Patients with congestive heart failure requiring drug treatment
3) Patients undergoing tests that involve intravascular administration of radioiodine contrast material (e.g., intravenous urography, intravenous cholangiography, angiography, computed tomography using contrast media, etc.) (can cause acute renal failure, and are associated with lactic acidosis in patients receiving this drug. Therefore, among patients scheduled for such tests, if the glomerular filtration rate is >60 mL/min/1.73 m2, at least at the time of the test or in advance The drug must be discontinued, and re-administration is not possible within 48 hours. In patients with moderate renal impairment (glomerular filtration rate ≥ 45 and <60 mL/min/1.73 m2), re-administration is not possible within 48 hours. Treatment is resumed only after it is confirmed that
4) Patients with known hypersensitivity to this drug or its components, such as anaphylaxis or angioedema [1. [See Warnings and 4. Adverse Reactions, 2) Post-Marketing Adverse Reactions]
5) Patients with acute or chronic metabolic acidosis including type 1 diabetes, lactic acidosis, diabetic ketoacidosis with or without coma, and patients with a history of ketoacidosis [Type 1 diabetes and diabetic ketoacidosis are treated with insulin.]
6) Diabetic precoma
7) In patients with severe infections or severe traumatic systemic disorders, treatment with this drug should be temporarily stopped and treatment should be restarted when the patient's oral intake is restored and renal function is found to be normal (see Dosage and Administration section). In the case of surgical procedures (except for minor surgeries where food and fluid intake is not restricted), this drug should be temporarily discontinued 48 hours before surgery, and treatment should be restarted at least 48 hours later when renal function is confirmed to be normal.
8) Patients with malnutrition, starvation, weakness, pituitary dysfunction, or adrenal dysfunction
9) Hepatic dysfunction (since impaired liver function is associated with some cases of lactic acidosis, administration of this drug should generally be avoided in patients with clinical or laboratory evidence of liver disease), pulmonary infarction, patients with severe pulmonary dysfunction and other conditions prone to hypoxemia, excessive alcohol intake, and patients with gastrointestinal disorders such as dehydration, diarrhea, and vomiting.
10) Pregnant women, women who may be pregnant, and lactating women

3. Administer with caution to the following patients:
(There is a possibility of lactic acidosis and hypoglycemia.)
1) Irregular meals, insufficient meal intake
2) Intense muscle exercise
3) Patients taking interacting drugs

4. Adverse reactions
1) Clinical trials
Because clinical trials are conducted under a wide range of diverse conditions, the incidence of adverse reactions observed in clinical trials cannot be directly compared to the rates in clinical trials of other drugs, and cannot reflect the rates observed under actual use environments.
In a placebo-controlled clinical trial, the addition of 100 mg of sitagliptin was well tolerated in patients with type 2 diabetes mellitus receiving metformin alone. The incidence of adverse reactions reported in patients receiving sitagliptin and metformin in combination was similar to that reported in patients receiving placebo and metformin in combination.
Initial therapy with sitagliptin and metformin
In a placebo-controlled factorial design clinical trial conducted for 24 weeks, adverse reactions reported at a frequency of 5% or more and more frequently than placebo, regardless of causality evaluation, when initially coadministering 50 mg of sitagliptin and 500 mg or 1,000 mg of metformin twice daily are shown in Table 1.
Table 1. Initial combination therapy with sitagliptin and metformin: adverse reactions reported at a frequency greater than 5% and more frequently than placebo, regardless of causality assessment†
* Table: refer to manual
† Intent-to-treat subject group
‡ Integrated data of patients receiving low and high doses of metformin.
Additional concomitant administration of sitagliptin in patients who cannot adequately control blood sugar levels with metformin monotherapy
In a 24-week placebo-controlled clinical trial, when sitagliptin 100 mg was additionally administered to patients taking metformin twice daily, there were no adverse reactions reported at a frequency of 5% or more and more frequently than placebo, regardless of causality assessment. Discontinuation of treatment due to adverse reactions was similar to the placebo group (sitagliptin + metformin 1.9%, placebo + metformin 2.5%).
Gastrointestinal adverse reactions
The incidence of specific gastrointestinal adverse reactions reported in patients receiving sitagliptin and metformin in combination was similar to that reported in patients receiving metformin alone (see Table 2).
Table 2. Specific gastrointestinal adverse reactions reported in patients receiving sitagliptin and metformin concomitantly, regardless of causality assessment†
* Table: refer to manual
† In initial therapy trials, abdominal pain included abdominal discomfort.
‡ Integrated data of patients receiving low and high doses of metformin
Combined administration of metformin, sulfonylurea, and sitagliptin
In a placebo-controlled 24-week clinical trial (116 patients with sitagliptin, 113 patients with placebo) of additional co-administration of 100 mg of sitagliptin in patients with type 2 diabetes who were unable to adequately control blood sugar levels with glimepiride and metformin, adverse reactions reported at a frequency of 5% or more and more frequently than placebo, regardless of causality assessment, were hypoglycemia (see Table 3) and headache (sitagliptin). 6.9%, placebo 2.7%).
Combined administration of metformin, rosiglitazone, and sitagliptin
In a placebo-controlled trial of sitagliptin 100 mg added to rosiglitazone and metformin in patients with type 2 diabetes whose glycemic control was inadequate (181 receiving sitagliptin and 97 receiving placebo), adverse events reported through week 18 at a frequency of at least 5% and more frequently than with placebo, regardless of causality, were upper respiratory tract infection (sitagliptin 5.5%, placebo 5.2%) and nasopharyngitis (6.1%, 4.1%). At week 54, the corresponding events were upper respiratory tract infection (15.5%, 6.2%), nasopharyngitis (11.0%, 9.3%), peripheral edema (8.3%, 5.2%), and headache (5.5%, 4.1%).
Combined administration of metformin, insulin, and sitagliptin
In a 24-week placebo-controlled clinical trial (229 patients with sitagliptin, 233 patients with placebo) of the additional co-administration of 100 mg of sitagliptin in patients with type 2 diabetes who were unable to achieve sufficient glycemic control with stable doses of insulin and metformin, the only adverse reaction reported at a frequency of 5% or more and more frequently than placebo, regardless of causality assessment, was hypoglycemia (see Table 3). In another 24-week clinical trial conducted in patients receiving sitagliptin as add-on therapy during the insulin intensification period (±metformin), there were no adverse reactions reported in patients receiving sitagliptin and metformin at a frequency greater than 5% and more frequently than those receiving placebo and metformin, regardless of causality assessment.
low blood sugar
In all studies (5), hypoglycemic adverse events were based on reports of symptomatic hypoglycemia. Although blood sugar measurement was not necessarily required, most reports of hypoglycemia (77%) were below 70 mg/dL when measured. When sitagliptin and metformin were administered in combination with a sulfonylurea or insulin, the proportion of patients with one or more hypoglycemic events was higher than in the placebo group (see Table 3).
Table 3. Placebo-controlled clinical trials of sitagliptin and metformin in combination with sulfonylureas or insulin: reported incidence of hypoglycemia, regardless of causality assessment*
* Table: refer to manual
* Hypoglycemic adverse events were based on reports of symptomatic hypoglycemia and were not necessarily accompanied by blood glucose measurements; Intent to treat
† Based on total number of incidents (one person may report multiple incidents)
‡ Severe hypoglycemia was defined as requiring medical attention, being at a reduced level of consciousness, losing consciousness, or having a seizure.
The total incidence of hypoglycemic adverse reactions was 0.6% in the placebo group, 0.6% in the group administered sitagliptin alone, 0.8% in the group administered metformin alone, and 1.6% in the group administered metformin and sitagliptin in combination in patients with type 2 diabetes whose blood sugar was not sufficiently controlled by diet and exercise therapy. In type 2 diabetes patients whose blood sugar was not sufficiently controlled with metformin alone, the rate was 1.3% when sitagliptin was added in combination, and when placebo was added, the rate was 2.1%.
In a study in which sitagliptin was administered in combination with rosiglitazone and metformin, the incidence of hypoglycemia was 2.2% in the sitagliptin group and 0.0% in the placebo group by week 18, and was 3.9% and 1.0%, respectively, by week 54.
Vital Signs and Electrocardiogram (ECG)
No clinically significant changes in vital signs or ECG (including QTc interval) were observed with sitagliptin and metformin co-administration.
pancreatitis
When the results of 19 double-blind clinical trials of 10,246 patients randomly assigned to sitagliptin 100 mg/day (N=5429) or the corresponding control group (active control or placebo) (N=4817) were pooled and analyzed, the incidence of acute pancreatitis in each group was 0.1 per 100 patient-years (in the sitagliptin group) reported in 4 patients out of 4708 patient-years and in the control group in 4 patients out of 3942 patient-years). In the TECOS cardiovascular safety trial, the incidence of acute pancreatitis was reported to be 0.11 (23/7,332, 25 cases) per 100 patient-years in the sitagliptin group and 0.06 (12/7,339, 17 cases) per 100 patient-years in the placebo group. [Refer to 1. Warning, Sitagliptin, 2) Pancreatitis section, TECOS Cardiovascular Safety Clinical Trial section]
Sitagliptin
Among the adverse reactions reported with sitagliptin monotherapy at a frequency of more than 5% and more frequently than placebo, regardless of causality assessment, the most frequently reported adverse reaction was nasopharyngitis.
metformin
Among the established adverse reactions from metformin therapy, the most frequently reported adverse reactions (>5%) are diarrhea, nausea/vomiting, gastrointestinal bloating, abdominal discomfort, dyspepsia, asthenia, and headache.
TECOS Cardiovascular Safety Trial (TECOS: Trial Evaluating Cardiovascular Outcomes with Sitagliptin)
The intent-to-treat (ITT) group of the sitagliptin cardiovascular safety clinical trial included 7,332 patients who received sitagliptin 100 mg daily (or 50 mg daily if eGFR ≥30 and <50 mL/min/1.73 m2 at baseline) and 7,339 patients who received placebo. In this trial, sitagliptin or placebo was administered in addition to usual treatment in each country related to HbA1c and cardiovascular (CV) risk factors. Sitagliptin administration did not increase the risk of hospitalization due to major cardiovascular disease or heart failure (see section 11. Information for experts). The incidence of serious adverse reactions reported was similar at 12.7% in the sitagliptin group and 12.4% in the placebo group.
Severe hypoglycemia was reported in 2.2% of the sitagliptin group (160 patients; 0.78 per 100 patient-years) and 1.9% of the placebo group (143 patients; 0.70 per 100 patient-years). Among patients receiving insulin and/or a sulfonylurea, the incidence was 2.7% with sitagliptin (138/5,021 patients) and 2.5% with placebo (125/4,931 patients). Among patients not receiving insulin or a sulfonylurea, the incidence was 1.0% with sitagliptin (22/2,311 patients) and 0.7% with placebo (18/2,408 patients). Confirmed acute pancreatitis occurred in 0.3% of the sitagliptin group and 0.2% of the placebo group.
laboratory tests
Sitagliptin
The incidence of laboratory adverse reactions in the group administered 100 mg of sitagliptin was 8.2%, and in the group administered placebo, it was 9.8%. In clinical trials, a slight increase in white blood cell count (approximately 200 cells/μL difference compared to placebo administration; average baseline value of approximately 6600 cells/μL) was observed due to an increase in neutrophils. This difference has been shown in many, but not all, studies, and changes in laboratory values ​​are not believed to be clinically relevant.
In a 12-week study, 91 patients with chronic renal impairment and 37 patients with moderate renal impairment were randomly assigned to sitagliptin 50 mg, and 14 patients with the same degree of renal impairment were randomized to placebo. The mean (standard error) increase in serum creatinine was 0.12 mg/dL (0.04) in the sitagliptin group and 0.07 mg/dL (0.07) in the placebo group. The clinical significance of increased serum creatinine compared to placebo is unknown.
metformin hydrochloride
In a 29-week controlled clinical trial of metformin, it was observed that in approximately 7% of patients, serum vitamin values, which were normal before the trial, decreased below normal without clinical symptoms. However, this decrease, which is thought to be due to inhibition of B12 absorption from the B12-intrinsic factor complex, is very rarely accompanied by anemia, and is quickly recovered by discontinuing metformin administration or supplementing with vitamin B12.
2) Post-marketing adverse reactions
The following are adverse reactions that were additionally confirmed after the marketing of sitagliptin, regardless of whether it was administered in combination with metformin, and regardless of whether it was administered in combination with other hypoglycemic agents. Because these adverse reactions are voluntarily reported from an unspecified population, it is generally not possible to reliably predict their frequency or establish a causal relationship with drug exposure.
Hypersensitivity reactions, including anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis, and exfoliative skin diseases, including Stevens-Johnson syndrome [1. Warning, sitagliptin, 1) hypersensitivity reaction and 2. [See Do not administer to the following patients]; Increased liver enzyme levels; Acute pancreatitis, including fatal/non-fatal hemorrhagic or necrotizing pancreatitis [1. Warning, see tagliptin, 2) pancreatitis]; Deterioration of renal function, including acute renal failure (sometimes requiring dialysis); upper respiratory tract infection; nasopharyngitis; constipation; puke; headache; Severe and disabling arthralgia [5. General precautions, see section 15) Severe and disabling arthralgia]; Bullous pemphigus [5. See General Precautions, 17) Bullous Pemphigoid]; myalgia; Pain in limbs; back pain; interstitial lung disease; pruritus; thrombocytopenia; rhabdomyolysis
Vitamin B12 deficiency is common when taking metformin.
3) Domestic post-marketing survey results
① As a result of a use result survey conducted on 4,033 people over 6 years for re-examination in Korea, the incidence of adverse events was reported to be 3.74% (151/4,033 people) [199 cases] regardless of causal relationship, and among these, the incidence of adverse drug reactions for which a causal relationship with this drug cannot be ruled out was 1.64% (66/4,033 people) [82 cases]. ‘Nausea’ 0.45% (18/4,033 people) [20 cases], ‘hypoglycemia’ 0.35% (14/4,033 people) [16 cases], and ‘diarrhea’ 0.17% (7/4,033 people) [7 cases] were reported.
Regardless of the causal relationship, serious adverse events were 0.42% (17/4,033 people) [23 cases], including ‘difficulty breathing’ and ‘unstable angina’, respectively, at 0.05% (2/4,033 people) [2 cases], and ‘abdominal pain’, ‘vomiting’, ‘headache’, ‘dizziness’, and ‘acute renal failure’ respectively. It was reported at 0.02% (1/4,033 people) [1 case], and among these, the serious adverse drug reaction was ‘acute renal failure’ at 0.02% (1/4,033 people) [1 case].
Unexpected adverse events were reported at 1.88% (76/4,033 people) [97 cases] regardless of causal relationship, ‘reduced appetite’ at 0.12% (5/4,033 people) [5 cases], ‘itching’ and ‘dizziness’ at 0.1% (4/4,033 people) [4 cases] and [5 cases] respectively. Among these, this drug and Unexpected adverse drug reactions for which a causal relationship cannot be ruled out were 0.47% (19/4,033 people) [20 cases], ‘decreased appetite’ at 0.12% (5/4,033 people) [5 cases], ‘gastrointestinal disorder’, ‘itching’ at 0.07% each (3/4,033 people) [3 cases], and ‘dizziness’. It was reported as 0.05% (2/4,033 people) [2 cases].
② As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect reporting data for this drug with the adverse event reporting data reported for all domestically approved drugs at the end of re-examination, the following are newly identified adverse events that were statistically significantly more reported for this drug compared to those reported for all other drugs. However, this result does not mean that a causal relationship has been proven between the ingredient and the following adverse events.
· Skin and appendage disorders: dermatitis
· Mental illness: loss of appetite
· Metabolic and nutritional diseases: weight loss

5. General precautions
1) Lactic acidosis: Lactic acidosis is rare but serious and is a metabolic complication that occurs due to accumulation of metformin during treatment with this drug. When it occurs, it is mostly associated with acute renal function deterioration, cardiopulmonary disease, and sepsis, and is fatal in 50% of cases. Lactic acidosis may occur when there is significant tissue hypoperfusion and hypoxia and in conjunction with pathophysiological conditions, including diabetes. Lactic acidosis is characterized by increased blood lactic acid concentration (>5 mmol/L), decreased blood pH (<7.35), electrolyte imbalance with increased difference between anions, and increased lactate/pyruvate ratio. When metformin is believed to be the cause of lactic acidosis, metformin blood concentrations generally exceed 5 μg/mL.
There are very few reports of the development of lactic acidosis in patients receiving metformin (approximately 0.03 cases per 1,000 patients per year and approximately 0.015 fatal cases per 1,000 patients per year). The reported cases primarily occurred in diabetic patients with significantly reduced renal function, including intrinsic renal disease and renal hypoperfusion, in conditions such as multiple medical and surgical problems and combined administration of many drugs (see Dosage and Administration, Patients with Renal Impairment). The risk of lactic acidosis increases depending on the degree of renal function decline and the patient's age (see section 9. Administration to the elderly, metformin hydrochloride).
In addition, metformin should be discontinued immediately if symptoms related to hypoxia, dehydration, or sepsis appear. If liver function is impaired, the ability to excrete lactic acid may be significantly reduced, so this drug is generally not administered to patients with clinical or laboratory findings of liver disease. Since alcohol has the potential to affect metformin's lactic acid metabolism, acute or chronic excessive intake of alcohol should be avoided while taking this drug.
The onset of lactic acidosis is sometimes difficult to distinguish and is accompanied by nonspecific symptoms such as malaise, myalgia, dyspnea, asthenia, and abdominal pain. If acidosis becomes more severe, a drop in body temperature, hypotension, and resistant bradyarrhythmia may occur. Patients and doctors should be aware of the importance of these symptoms, and patients should notify their doctors immediately if these symptoms occur. Serum electrolytes, ketones, blood sugar, blood pH, lactic acid levels, and blood levels of this drug may also be useful in confirming lactic acidosis. Additionally, if there is a high suspicion of lactic acidosis, necessary measures are taken without expecting a lactic acid measurement result. In particular, be careful because lactic acidosis is likely to occur when the initial dose is increased. Gastrointestinal symptoms often occur early in treatment once the patient has stabilized on a specific dose of metformin, but later gastrointestinal symptoms may be due to lactic acidosis or another serious illness.
Fasting venous plasma lactate concentrations above the upper limit of normal but below 5 mmol/L in patients receiving metformin do not indicate impending lactic acidosis and may be due to other mechanisms, such as poorly controlled diabetes or obesity, excessive physical activity, or technical problems in specimen handling. Lactic acidosis should be suspected in diabetic patients presenting with metabolic acidosis without evidence of ketoacidosis (ketonuria and ketonemia).
Lactic acidosis is a medical emergency requiring hospitalization. If lactic acidosis occurs in a patient taking this drug, the drug should be discontinued immediately and general supportive treatment should be administered immediately. Since the drug is dialyzable (clearance up to 170 mL/min in good hemodynamic conditions), immediate hemodialysis is recommended to normalize acidosis and remove accumulated drug. This treatment sometimes results in immediate symptom improvement and recovery.
2) Patients with hepatic impairment: Because hepatic impairment is associated with some cases of lactic acidosis, this drug should generally be avoided in patients with clinical or laboratory evidence of liver disease.
3) Monitoring renal function: Metformin and sitagliptin are known to be mostly excreted through the kidneys, and the risk of metformin accumulation and lactic acidosis increases depending on the degree of renal function impairment. Therefore, patients with serum creatinine levels above the upper limit of normal for their age should not take this drug.
Before starting treatment with this drug, and at least annually, a renal function test must be performed to confirm normality. Patients with creatinine clearance lower than normal and the elderly should have a renal function test performed at least 2 to 4 times a year. If creatinine clearance <45ml/min or glomerular filtration rate <45ml/min/1.73m2), discontinue treatment with this drug. Special caution is needed in situations that may lead to rapid renal function impairment, such as those experiencing dehydration (severe or persistent vomiting or diarrhea) or starting medications that affect renal function (such as antihypertensive drugs or diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs)). In these acute situations, metformin should be discontinued immediately and temporarily.
4) Vitamin B12 level: It is recommended to monitor serum vitamin B12 level annually. The risk of low vitamin B12 levels increases in patients with higher metformin doses, longer treatment duration, and/or with risk factors known to cause vitamin B12 deficiency.
5) Alcohol consumption: Alcohol is known to increase the effect of this drug on lactic acid metabolism. Therefore, acute or chronic excessive intake of alcohol should be avoided while taking this medicine.
6) Surgery: During the surgical procedure, administration of this drug should be temporarily suspended (excluding mild procedures with no restrictions on food and fluid intake) and administered again after the patient's oral intake is restored and renal function is assessed as normal.
7) Changes in patients with controlled type 2 diabetes: If abnormal laboratory findings or clinical disease (especially vague and poorly defined disease) occurs in a patient whose type 2 diabetes was previously well controlled with this drug, the patient should be immediately evaluated for the development of ketoacidosis or lactic acidosis. Serum electrolytes, ketones, and blood sugar are tested, and, if necessary, blood pH, lactate, pyruvate, and metformin levels. If any form of acidosis appears, immediately stop administering this drug and take other appropriate and correct measures.
8) Low blood sugar:
Sitagliptin
In clinical trials, when sitagliptin was administered alone or in combination with drugs known not to cause hypoglycemia (metformin or thiazolidinedione), the incidence of hypoglycemia was similar to that reported with placebo. As is typical with co-administration with other hypoglycemic agents, hypoglycemia was observed when sitagliptin was co-administered with insulin or sulfonylureas (see section 4. Adverse Reactions). To reduce the risk of hypoglycemia caused by sulfonylureas or insulin, a reduction in sulfonylureas or insulin may be considered. (Refer to the dosage and dosage section)
metformin hydrochloride
Hypoglycemia does not occur in patients who take metformin alone under normal use circumstances, but occurs when caloric intake is insufficient, when vigorous exercise is not supplemented by caloric intake, or when other hypoglycemic agents (sulfonylurea, insulin, etc.) or alcohol are administered concurrently. Hypoglycemia is especially likely to occur in the elderly, weak or malnourished patients, patients with adrenal or pituitary insufficiency, or alcoholics. Hypoglycemia may be difficult to identify in older adults and people taking β-adrenergic blocking drugs. When symptoms of hypoglycemia are recognized due to administration of metformin, sugar (sucrose) is generally administered, and when symptoms of hypoglycemia are recognized due to concurrent use with an α-glucosidase inhibitor (acarbose, voglibose), glucose is administered.
9) Co-administration with drugs that may affect renal function or metformin metabolism or excretion: Co-administration with drugs that may affect renal function, cause significant hemodynamic changes, or inhibit the metabolism or excretion of metformin, such as cationic drugs excreted through renal tubular discharge, should be used with caution.
10) Hypoxic states: Cardiovascular collapse (shock) of any cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxia are associated with lactic acidosis and may cause prerenal azotemia. If this occurs in a patient receiving treatment with this drug, administration of this drug should be discontinued immediately.
11) Patients with specific occupations: Metformin, one of the ingredients of this drug, may rarely cause severe lactic acidosis and severe delayed hypoglycemia, so be careful when administering it to patients engaged in work at heights or driving a car. In addition, provide sufficient and thorough warning to patients and their families regarding lactic acidosis and hypoglycemia.
12) Patients should be informed of the potential benefits and risks of this drug and other treatment methods. In addition, they should be informed of the importance of maintaining a diet, regular exercise plan, regular blood sugar tests, glycated hemoglobin, renal function, and hematological values.
The risk of lactic acidosis caused by metformin, one of the ingredients of this drug, its symptoms, and possible predispositions should be explained to the patient. If unexplained hyperventilation, muscle pain, fatigue, abnormal confusion, or other unspecified symptoms occur, stop taking this medication immediately and notify your medical staff.
Advise patients about the risks of excessive alcohol consumption, whether acute or chronic, while taking this medicine.
13) Initial and regular monitoring of hematological values (e.g. hemoglobin/hematocrit, red blood cell index) and renal function (serum creatinine) should be performed at least once a year. Megaloblastic anemia is rarely observed during treatment with metformin, and if suspected, the possibility of vitamin B12 deficiency should be checked.
14) Concurrent administration with drugs known to cause hypoglycemia
Sitagliptin
As is typical with co-administration with other hypoglycemic agents, hypoglycemia was observed when sitagliptin was co-administered with insulin or sulfonylureas (see section 4. Adverse Reactions). Therefore, to reduce the risk of hypoglycemia caused by insulin secretion stimulating agents (e.g. sulfonylurea, meglitinide), a reduction in insulin secretion stimulating agents may be considered.
metformin hydrochloride
Under normal administration conditions, hypoglycemia does not occur in patients taking metformin alone, but it can occur when caloric intake is insufficient, when caloric supplementation is not achieved after intense exercise, or when other blood sugar lowering agents (sulfonylureas, insulin) or alcohol (ethanol) are co-administered. Elderly or undernourished patients and those with adrenal or pituitary hyperfunction or alcoholism may be particularly sensitive to hypoglycemia. Hypoglycemia is difficult to recognize in elderly people and people taking β-adrenergic blockers.
15) Severe and disabling joint pain
Severe and disabling arthralgia have been reported in post-marketing studies in patients taking DPP-4 inhibitors. The onset of symptoms after drug administration varied from 1 day to several years later. Symptoms were alleviated when drug administration was stopped. In some patients, recurrence of symptoms occurred when taking the same drug or a different DPP-4 inhibitor. Consider the DPP-4 inhibitor as the cause of severe arthralgia and, if appropriate, discontinue administration.
16) Results regarding macrovascular disease complications: There are no clinical trials confirming that this drug or other oral hypoglycemic agents reduce the risk of macrovascular disease complications.
17) Bullous pemphigoid
In post-marketing surveillance in patients taking DPP-4 inhibitors, cases of bullous pemphigus requiring hospitalization have been reported. Patients generally recovered with discontinuation of DPP-4 inhibitors and treatment with local or systemic immunosuppressants. Patients should be advised to immediately report to their doctor if blisters or sores occur while taking this medication. If bullous pemphigus is suspected, this drug should be discontinued and the patient should be referred to a dermatologist for diagnosis and appropriate treatment.

6. Interaction
When 50 mg of sitagliptin and 1000 mg of metformin were administered repeatedly twice daily in patients with type 2 diabetes, neither drug caused significant pharmacokinetic changes.
Studies on the pharmacokinetic drug interactions of this drug have not been conducted, but studies have been conducted on sitagliptin and metformin, respectively.
Sitagliptin
In drug interaction studies, sitagliptin did not have a clinically significant effect on the pharmacokinetics of the following drugs: metformin, rosiglitazone, glibenclamide, simvastatin, warfarin, and oral contraceptives.
Cyclosporine: When administered as a single dose in combination with 600 mg of cyclosporine, a strong p-glycoprotein inhibitor, the AUC (29%) and Cmax (68%) of sitagliptin increased, but the change in the pharmacokinetics of sitagliptin is not expected to be clinically significant. No significant interaction is expected when coadministered with cyclosporine or other p-glycoprotein inhibitors.
Digoxin: When coadministered with 100 mg of sitagliptin for 10 days, the plasma AUC (11%) and Cmax (18%) of digoxin increased slightly. Appropriate monitoring should be conducted when administering digoxin, and dose adjustment of sitagliptin and digoxin is not necessary.
metformin hydrochloride
1) Since the blood sugar lowering effect may be enhanced or reduced by combined use with the following drugs, when used together, administer while carefully observing the blood sugar level and the condition of other patients.
- Drugs that enhance blood sugar lowering action
Insulin preparations, sulfonamide and sulfonylurea drugs, α-glucosidase inhibitors, anabolic steroids, guanethidine, salicylates (aspirin, etc.), β-blockers (propranolol, etc.), MAO inhibitors, angiotensin converting enzyme inhibitors
- Drugs that reduce blood sugar lowering action
Epinephrine, sympathomimetics, corticosteroids, thyroid hormones, follicular hormones, estrogens, oral contraceptives, thiazide and other diuretics, pyrazinamide, isoniazid, nicotinic acid, phenothiazines, phenytoin, calcium channel antagonists.
2) Alcohol: The risk of lactic acidosis increases during the acute alcohol intoxication period, especially in the following circumstances.
- Hungry or malnutrition
- Liver dysfunction
You should avoid drinking alcohol and taking drugs that contain alcohol.
3) Iodine-labeled contrast media: Renal failure may occur in association with intravenous administration of iodine-labeled contrast media, which may lead to accumulation of metformin and potentially expose patients to the risk of lactic acidosis. Metformin administration should be discontinued before or at the time of testing using iodine-labeled contrast media, and administered again at least 48 hours later and after confirmation of normal renal function.
4) Glibenclamide: In a single-dose study on patients with type 2 diabetes, co-administration of metformin and glibenclamide did not change the pharmacokinetics or pharmacodynamic properties of metformin. A decrease in the AUC and Cmax of glibenclamide was observed, but the deviation was large. The lack of correlation between blood concentrations and pharmacokinetic effects of single-dose glibenclamide in this study indicates that the clinical significance of this interaction is unclear.
5) Furosemide: Through a drug interaction test of metformin-furosemide administered as a single dose to healthy volunteers, it was demonstrated that the pharmacokinetic values of each substance are affected by co-administration. Furosemide did not significantly change the renal clearance of metformin, but increased the blood Cmax and blood AUC of metformin by 22% and 15%, respectively. When co-administered with metformin, the Cmax and AUC of furosemide were reduced by 31% and 12%, respectively, compared to single administration, and the terminal half-life of furosemide was reduced by 32% without changing the renal clearance of furosemide. There is no available information regarding the interaction of chronic co-administration of metformin and furosemide.
6) Nifedipine: Through a drug interaction test of metformin-nifedipine administered as a single dose to healthy volunteers, when co-administered with nifedipine, the plasma Cmax and AUC of metformin increased by 20% and 9%, respectively, and urinary excretion increased. There was no effect on Tmax and half-life. Nifedipine increased the absorption of metformin. Metformin has minimal effect on nifedipine.
7) Drugs that may affect this drug, such as cationic drugs that may affect renal function, cause significant hemodynamic changes, affect specific hepatic or renal transporters, or are excreted through renal tubular secretion: Metformin is a substrate of the Organic Cation Transporter (OCT) OCT1, OCT2, and multidrug and toxin extrusion (MATE) transporters.
- When used in combination with OCT1 inhibitors (verapamil, etc.), the efficacy of metformin may be reduced.
- When used in combination with OCT1 inducers (rifampicin, etc.), the gastrointestinal absorption and efficacy of metformin may increase.
- When used in combination with OCT2 and MATE inhibitors (cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, etc.), the renal excretion of metformin may be reduced and the blood concentration of metformin may increase.
- When used in combination with OCT2 and OCT1 simultaneous inhibitors (crizotinib, olaparib), the renal excretion and efficacy of metformin may be affected.
Therefore, when metformin and these drugs are administered together, the blood concentration of metformin may increase, so caution is needed, especially in patients with renal impairment. Since OCT inhibitors/inducers may change the efficacy of metformin, dose adjustment of metformin may be considered if necessary.
In addition, non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-II (Cyclo-oxygenase) inhibitors, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor antagonists, and diuretics (especially loop diuretics) may have an adverse effect on renal function and increase the risk of lactic acidosis. Therefore, renal function should be carefully monitored when administered in combination with metformin. Must observe.
8) Others: In a single-dose co-administration study in healthy volunteers, the pharmacokinetic properties of metformin and propranolol and metformin and ibuprofen were not affected by each other. Metformin's binding to plasma proteins is negligible, so interactions with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid are expected to be minimal.

7. Administration to pregnant and lactating women
1) Administration to pregnant women
The safety of this drug in pregnant women is not known because there are no appropriate controlled studies on this drug or its components in pregnant women. Therefore, it should not be administered to pregnant women or women who may be pregnant.
2) Administration to nursing mothers
Sitagliptin has been reported to be secreted into breast milk in rats, so it is not administered to nursing mothers.

8. Administration to children
The safety and effectiveness of this drug in pediatric patients under 18 years of age have not been established.
The safety and efficacy of sitagliptin in combination (administered as Janumet tablets or Janumet XR extended-release tablets) in pediatric patients aged 10 to 17 years with type 2 diabetes whose blood sugar was not adequately controlled by metformin alone or in combination with metformin and insulin was evaluated in two 54-week placebo-controlled clinical trials.
The integrated analysis of the two clinical trials showed that the HbA1c reduction effect of sitagliptin in combination with metformin background therapy was superior to placebo after 20 weeks of administration, but consistent results were not confirmed in each individual trial. Additionally, the effectiveness of sitagliptin in combination with placebo was not observed at week 54. Therefore, these results do not support the administration of this drug to pediatric patients aged 10 to 17 years with type 2 diabetes.
The adverse event profile of pediatric patients aged 10 to 17 years with type 2 diabetes was similar to that of adult patients. In pediatric patients, sitagliptin was associated with an increased risk of hypoglycemia, regardless of background insulin therapy.
This drug has not been tested in children under 10 years of age.

9. Administration to elderly people
Sitagliptin and metformin are known to be largely excreted through the kidneys. Since elderly people are prone to decreased renal function, the minimum dose to achieve appropriate blood sugar control effects should be set based on the patient's renal function. Elderly people should regularly monitor their renal function.
Sitagliptin
Of the total subjects (3,884) in the pre-approval clinical trial, 725 were over 65 years of age and 61 were over 75 years of age. Safety and efficacy in elderly patients over 65 years of age were similar to those in younger patients. Although there was no difference in responsiveness between this patient group and the younger patient group, it cannot be ruled out that susceptibility may be increased in some elderly patients.
metformin hydrochloride
Although there are clinical reports that there are no differences in response between elderly and adult patients, controlled clinical trials of metformin have not obtained a sufficient number of elderly patients to determine whether they respond differently from adults. Since aging is associated with a decrease in liver and kidney function (when liver function decreases, the ability to metabolize lactic acid decreases and lactic acidosis may occur), metformin should be administered with caution as age increases. Dosage decisions should be made with caution and based on careful and regular monitoring of renal function. In general, the maximum dose of metformin is not administered to elderly people.

10. Treatment in case of overdose
Sitagliptin
In clinical trials of this drug, single doses of up to 800 mg of this drug were administered to healthy adults. In a study administering 800 mg of sitagliptin, an increase in mean QTc up to 8.0 msec was observed, but this was not clinically relevant. There is no experience administering doses exceeding 800 mg in humans.
In case of overdose, general symptomatic treatment (e.g., removal of unabsorbed drug from the gastrointestinal tract and clinical monitoring including electrocardiogram) is performed, and auxiliary treatment is provided depending on the patient's condition.
Sitagliptin can be partially removed by dialysis. In clinical trials, approximately 13.5% of the administered dose was removed upon hemodialysis over 3 to 4 hours. Long-term hemodialysis should be considered if clinically appropriate. It is not known whether sitagliptin is removed by peritoneal dialysis.
metformin hydrochloride
Even administration of up to 85 g of metformin hydrochloride does not cause hypoglycemia even if lactic acidosis occurs under these conditions. Metformin is dialyzed with clearance rates reaching 170 mL/min under good hematological conditions. Therefore, hemodialysis may be useful to remove accumulated drug in patients suspected of overdosing with this drug.

11. Information for experts
1) Clinical trial information
A clinical trial was conducted to evaluate the effectiveness and safety of sitagliptin in combination with immediate-release metformin in patients with type 2 diabetes who had insufficient glycemic control when taking other hypoglycemic agents with diet and exercise therapy or with diet and exercise therapy. Although this drug was not administered directly in each test, bioequivalence between this drug and the combined administration of sitagliptin and metformin as single drugs has already been proven.
Initial combination therapy with metformin and sitagliptin
A 24-week, randomized, double-blind, placebo-controlled, factorial design clinical trial was conducted to evaluate the safety and effectiveness of initial combination therapy with sitagliptin and metformin in 1,091 patients with type 2 diabetes (HbA1c 7.5% to 11%) who had poor glycemic control with diet and exercise therapy.
In this trial, initial combination therapy with sitagliptin and metformin demonstrated significant improvement in HbA1c compared to placebo, metformin monotherapy, or sitagliptin monotherapy (Table 4), as well as statistically significant reductions in FPG and 2-h PPG (p<0.001). Compared to the placebo group, the mean reduction from baseline in HbA1c was generally greater in patients with higher baseline HbA1c.
Table 4. Results of a 24-week clinical trial comparing the effectiveness of the initial combination of metformin and sitagliptin with each monotherapy in patients with type 2 diabetes who have poor blood sugar control with diet and exercise therapy†
* Table: refer to manual
†Cohort of all patients who received the drug (intention-to-treat analysis).
‡ Least square means were adjusted for previous hypoglycemic agent therapy and baseline conditions.
§ p<0.001
Addition of sitagliptin to metformin monotherapy
A 24-week, randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the safety and effectiveness of the additional use of 100 mg of sitagliptin in 701 patients with type 2 diabetes (HbA1c 7% to 10%) who had poor glycemic control with metformin (?1500 mg/day). At 24 weeks, the additional combination of sitagliptin 100 mg once daily to metformin background therapy showed a statistically significant improvement in HbA1c compared to placebo (Table 5), and a significant decrease in FPG and 2-h PPG compared to placebo (FPG, -25.4 mg/dL; 2-h PPG, -50.6 mg/dL). In predefined subgroup analyses, the improvement in HbA1c compared to placebo was not affected by baseline HbA1c, previous antidiabetic medication, gender, age, baseline BMI, time since diabetes diagnosis, presence of metabolic syndrome, or standard index of insulin resistance (HOMA?IR) or standard index of insulin secretion (HOMA?β).
Table 5. Results of evaluating the effectiveness of sitagliptin in combination with type 2 diabetes in patients with poor glycemic control with metformin (24 weeks)†
* Table: refer to manual
†Cohort of all patients who received the drug (intention-to-treat analysis).
‡Least square means were adjusted for previous hypoglycemic agent therapy and baseline status.
§ p<0.001
Active-controlled clinical trial comparing the add-on use of sitagliptin to metformin with glipizide
A 52-week, randomized, double-blind, active-controlled clinical trial was conducted to evaluate the effectiveness and safety of sitagliptin 100 mg once daily compared to the additional combination of glipizide (maximum 20 mg/day) in 1,172 type 2 diabetes patients (HbA1c 6.5%~10%) who had poor glycemic control with metformin (?1500 mg/day) monotherapy. The initial dose of glipizide was 5 mg/day, and the dose was increased up to 20 mg/day to optimize glycemic control for 18 weeks, and the subsequent dose was kept constant (average glipizide dose 10.3 mg/day). In this test, HbA1c was significantly improved compared to baseline in both administration groups. After 52 weeks, the reduction in HbA1c compared to baseline was similar at -0.67% in the sitagliptin 100 mg once daily group and -0.67% in the glipizide group.
Addition of sitagliptin to metformin and glimepiride combination therapy
A 24-week, randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the efficacy and safety of the additional combination of sitagliptin in 441 patients with type 2 diabetes (HbA1c 7.5% to 10.5%) who had poor glycemic control with glimepiride (?4 mg/day) monotherapy or combination therapy with glimepiride and metformin (?1500 mg/day). At 24 weeks, the additional combination of sitagliptin 100 mg once daily to glimepiride and metformin background therapy significantly improved HbA1c compared to placebo (Table 6), and a statistically significant decrease in FPG was also observed compared to placebo (-20.7 mg/dL).
Table 6. Results of evaluating the effectiveness of sitagliptin in combination with type 2 diabetes in patients with poor glycemic control with metformin and glimepiride combination therapy (24 weeks)†
* Table: refer to manual
†Cohort of all patients who received the drug (intention-to-treat analysis).
‡Least square means were adjusted for previous hypoglycemic agent therapy and baseline status.
§ p<0.001
Addition of sitagliptin to metformin and rosiglitazone combination therapy
A 54-week (18 weeks + 36 weeks extension), randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the efficacy and safety of the additional combination of sitagliptin 100 mg in 262 patients with type 2 diabetes (HbA1c 7%~10%) who had poor glycemic control with metformin (?1500 mg/day) and rosiglitazone (?4 mg/day). At 18 weeks, the additional combination of sitagliptin 100 mg once daily on metformin and rosiglitazone background therapy showed a statistically significant improvement in HbA1c compared to placebo (Table 7), and a decrease in FPG and 2-h PPG was also observed compared to placebo (FPG, -19.0 mg/dL; 2-h PPG, -37.9 mg/dL).
The reduction effect on HbA1c, FPG, and 2-hPPG evaluated at 54 weeks was similar to the results at 18 weeks.
Table 7. Results of evaluating the effectiveness of sitagliptin in combination with type 2 diabetes in patients with poor glycemic control with metformin and rosiglitazone (18 weeks)†
* Table: refer to manual
†Cohort of all patients who received the drug (intention-to-treat analysis).
‡Least square means were adjusted for previous hypoglycemic agent therapy and baseline status.
§p<0.001
Add-on use of sitagliptin to metformin and insulin combination therapy
A 24-week, randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the efficacy and safety of the additional use of sitagliptin 100 mg in 641 patients with type 2 diabetes (HbA1c 7.5% to 11%) who had poor glycemic control with insulin (+/- metformin) therapy. In the run-in period, patients received a stable dose of insulin (combined, long-acting, or intermediate) alone or in combination with metformin (?1500 mg/day), and no dose adjustments were allowed during this period.
At 24 weeks, the additional use of sitagliptin 100 mg to the metfor and insulin combination therapy showed a statistically significant improvement in HbA1c compared to placebo (Table 8), and a significant decrease in FPG and 2-h PPG compared to placebo (-18.3 mg/dL, -40.4%, respectively).
Table 8. Results of evaluating the effectiveness of the additional use of sitagliptin in patients with type 2 diabetes who have poor glycemic control with insulin therapy combined with metformin (24 weeks)†
* Table: refer to manual
†Cohort of all patients who received the drug (intention-to-treat analysis).
‡Least square means were adjusted for insulin use at the first visit (combined vs. noncombined [intermediate or continuous]) and baseline status.
§The interaction treatment by insulin class was not significant (p>0.10).
%p<0.001
An additional 24-week, randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the insulin-sparing effect of sitagliptin in 660 patients with poor glycemic control on insulin glargine (+/- metformin? 1500 mg). Baseline HbA1c was 8.74%, baseline insulin dose was 37 IU/day, and patients were instructed to increase their insulin glargine dose based on fingerstick fasting blood glucose levels. Glycemic endpoints including HbA1c and FPG were measured.
At 24 weeks, the increase in daily insulin dose was 19 IU/day in the sitagliptin 100 mg group and 24 IU/day in the placebo group, which was smaller in the sitagliptin 100 mg group (-5 IU/day compared to the placebo group, p=0.009), and was not affected by metformin administration.
TECOS Cardiovascular Safety Clinical Trial
The primary cardiovascular endpoint is a composite outcome of cardiovascular-related death, non-fatal myocardial infarction, non-fatal stroke, or first event of unstable angina requiring hospitalization. Secondary cardiovascular endpoints were first event of cardiovascular-related death, non-fatal myocardial infarction, or non-fatal stroke; first event of the individual components of the first-order composite variable; death from all causes; Hospitalizations due to congestive heart failure were included.
After a median follow-up period of 3 years, sitagliptin added to usual care did not increase the risk of major adverse cardiovascular events or hospitalization for heart failure (Table 9).
Table 9. Composite cardiovascular outcome and key secondary outcome rates
* Table: refer to manual
2) Toxicity test information
① Carcinogenicity, mutagenicity, fertility
Sitagliptin
A carcinogenicity test was conducted on male and female rats at doses of 50, 150, and 500 mg/kg/day of sitagliptin for 2 years. The incidence of combined liver adenoma/carcinoma increased in both sexes, and in females, the incidence of liver cancer increased at 500 mg/kg. Based on AUC comparison, this dose is almost 60 times the maximum recommended human dose (MRHD) of 100 mg/day. Liver tumors were not observed at 150 mg/kg, which is nearly 20 times the maximum recommended human dose.
A carcinogenicity test was conducted on male and female mice at doses of 50, 125, 250, and 500 mg/kg/day of sitagliptin for 2 years. At 500 mg/kg, which is almost 70 times the maximum recommended human dose, there was no increase in tumor occurrence in any organ. Sitagliptin was not shown to be mutagenic or cause chromosomal abnormalities in a series of genotoxicity studies, such as reverse mutation (Ames) test using bacteria, in vitro chromosomal aberration test and in vitro cytogenetic analysis using CHO cells, in vitro alkaline elution assay in rat liver cells, and in vivo micronucleus test using mouse hematopoietic cells.
In a rat fertility test, doses of 125, 250, and 1000 mg/kg were administered to males for 4 weeks before mating, at the time of mating, and until the end of mating (about 8 weeks in total), and to females, they were administered orally from 2 weeks before mating until the 7th day of pregnancy. No abnormalities in fertility were observed at 125 mg/kg (approximately 12 times the maximum recommended human dose). At high doses (25 and 100 times the maximum recommended human dose), a dose-independent increase in resorption was observed in females.
metformin hydrochloride
Metformin is not a primary or secondary regenerating drug or exhibits pharmacokinetic properties that lead to addiction.
Long-term carcinogenicity studies were conducted in rats (dose lasting 104 weeks) and mice (dose lasting 91 weeks) at doses of 900 mg/kg/day and 1500 mg/kg/day, respectively. This dose is approximately three times the human body's maximum daily allowance based on body surface area. There was no evidence of carcinogenicity associated with this drug in either male or female mice. Similarly, there was no tumorigenic potential for this drug in male rats. However, an increase in benign interstitial uterine polyps was observed in female rats administered at 900 mg/kg/day.
There was no evidence of the mutagenic potential of metformin in reverse mutation testing (S. typhimurium), genetic mutation testing (mouse lymphoma cells), chromosomal aberration testing (human lymphocytes), or in vivo micronucleus testing (mouse bone marrow cells).
Fertility of male and female rats was not affected by metformin when administered at a high dose of 600 mg/kg/day, or approximately twice the maximum tolerated dose based on body surface area.
② Reproductive toxicity
In reproductive toxicity studies conducted in rats and rabbits, there was no damage to fertility or fetuses when administered up to 125 mg/kg of this drug (corresponding to exposure 12 times the maximum recommended human dose). However, there are no controlled test results for pregnant women, and the results of reproductive toxicity tests in animals do not always predict reactions in humans, so use in pregnant women is not recommended.
When sitagliptin was administered to pregnant female rats and rabbits on days 6 to 20 of pregnancy (organ formation period), there were no teratogenic effects when administered at doses up to 250 mg/kg in rats and up to 125 mg/kg in rabbits, or approximately 30 or 20 times the maximum recommended human dose of 100 mg/day based on AUC comparison. When administered orally in rats at 1000 mg/kg/day (equivalent to approximately 100 times exposure of the maximum recommended human dose of 100 mg/day), the incidence of rib hypoplasia in offspring increased with higher doses.
Body weight decreased in both male and female rat pups administered orally at a dose of 1000 mg/kg/day from the 6th day of pregnancy to the 21st day of lactation. No abnormalities in function or behavior were observed.
After administration to pregnant rats, approximately 45% of sitagliptin passed through the placenta at 2 hours and 80% at 24 hours. In rabbits, the rate was approximately 66% at 2 hours and 30% at 24 hours after administration.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/box (10 tablets/AluAlu

7. Period of use
24 months from date of manufacture

Product Updates

Total 2items